Director/PDMR Shareholding

RNS Number : 2241V
GlaxoSmithKline PLC
05 August 2015
 

GlaxoSmithKline plc

 

Notification of Transactions of Directors and Persons Discharging Managerial Responsibility

 

Grant of Conditional Share Award under GlaxoSmithKline Performance Share Plan

 

I give below details of changes in the interests of the below-mentioned Person Discharging Managerial Responsibility ("PDMR") in the Ordinary Shares of the Company ("Ordinary Shares") as a result of an award made under the 2009 Performance Share Plan ("PSP") on 4 August, 2015.

 

This award was made following the completion and implementation of the three-way transaction with Novartis in recognition of Ms Walmsley's increased role and responsibility as CEO of the new joint venture, GSK Consumer Healthcare.      

 

PDMR

 

Number of Ordinary Shares subject to the award

Emma Walmsley

59,493

 

The PSP was approved by shareholders on 20 May 2009, and allows a performance-related opportunity in the form of conditional awards to be made to senior executives in the Group, including the Executive Directors.

 

Under the terms of the PSP, a conditional award is granted over a specific number of Ordinary Shares, and the percentage of the award that ultimately vests is dependent on the level of achievement against performance targets set by the Remuneration Committee.  This award is conditional on three equally weighted performance measures, as set out in announcements from the Company on 12 February and 31 July 2015.

 

Dividends will accrue on the conditional award of Ordinary Shares during the three-year performance period, but will only vest to the extent that the awards themselves vest at the end of the performance period.  

 

The vesting date for this conditional award will be the date, following the end of the three year performance period, on which the Remuneration Committee determines the extent to which the performance conditions have been achieved or such other later date as determined by the Remuneration Committee.

 

The above conditional award was made on 4 August 2015.   The closing price of an Ordinary Share on 4 August 2015 was £14.01.

 

The Company and Ms Walmsley were advised of this transaction on 5 August 2015.

 

This notification is made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

 

V A Whyte

Company Secretary

 

 

5 August 2015


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSZELFBEVFXBBV

Companies

GSK (GSK)
UK 100

Latest directors dealings